Section 32

Endor Labs specializes in enhancing application security by managing open-source software dependencies. The company provides a Dependency Lifecycle Management Platform designed to tackle vulnerabilities within the software supply chain, particularly the unmanaged proliferation of open-source software in enterprises. By streamlining the selection, security, and maintenance of software dependencies, Endor Labs aids developers in adopting safe open-source solutions, thereby accelerating development processes and reducing the time spent on security issues. The platform supports clients in maximizing code reuse and implementing microservices architectures, ultimately simplifying the complexities associated with software engineering.

Character Therapeutics is a patient-driven therapeutics company that uses genomics, longitudinal clinical and imaging data, machine learning, and novel experimental approaches to identify the molecular drivers of disease progression and develop innovative targeted medicines. Its dedication to patients is reflected in the high standards set to ensure privacy, data security, ethics, scientific rigor, and a meaningful impact on patient health. To enable clinical genomic research, the company collaborates with patients, providers, payers, and scientists to create deeply phenotyped patient cohorts.

Sola Security is a cyber security company currently in Stealth mode.

Network Bio operates a clinical and molecular data library focused on facilitating precision medicine for common human diseases. Its platform serves as a centralized repository for clinical and molecular data, allowing researchers to analyze patterns and correlations. This analysis can lead to the development of new treatments and diagnostic tools, thereby advancing medical research and improving patient outcomes.

SandboxAQ is a company that develops artificial intelligence and quantum technology solutions aimed at addressing complex business and scientific challenges. By integrating expertise from multiple disciplines, including physics, computer science, and mathematics, the company creates Large Quantitative Models and AI sensing applications tailored for various industries. Its offerings are designed to provide practical solutions in sectors such as financial services, healthcare, telecommunications, and cybersecurity. Through its innovative software, SandboxAQ enables clients to tackle significant computational challenges and advance their technological capabilities.

TollBit is a content monetization platform that allows AI bots and data scrapers to pay websites directly to license their content and protects the health of the entire content ecosystem.

Sunbird Bio is a diagnostics platform developer focused on advancing molecular diagnostics to deliver faster and more accurate results. Founded by Huilin Shao, the company specializes in detecting a wide array of diseases, including infectious diseases, neurodegenerative disorders, and cancer. By enabling early diagnosis, Sunbird Bio aims to enhance healthcare outcomes and support physicians in making informed decisions. The platform is designed to improve clarity and accessibility in diagnostic testing, thereby contributing to better patient care.

Basecamp Research specializes in mapping biodiversity to facilitate the AI-driven design of biological systems. The company utilizes its advanced platform, BaseGraph™, which leverages a high-resolution map of global genetic diversity to match and refine novel proteins tailored to specific industrial, therapeutic, or diagnostic needs. By comprehensively understanding the genetic, evolutionary, and environmental contexts of proteins, Basecamp Research can create customized solutions without relying on costly and time-intensive directed evolution methods. The team comprises explorers, scientists, and policy experts dedicated to harnessing nature's diversity to deliver innovative breakthroughs and contribute to a cleaner, healthier, and more sustainable future.

Nusano is a physics firm focused on the production of radioisotopes, which are essential for diagnosing and treating cancer and other medical conditions. The company has developed a current ion source and linear accelerator that aim to overcome existing limitations in radioisotope manufacturing for medical applications. By producing a diverse array of diagnostic and therapeutic radioisotopes without the use of uranium, Nusano supports healthcare clients in creating radiopharmaceuticals for personalized cancer therapies. This innovative approach allows for the development of these critical medical products at comparatively lower costs, enhancing accessibility and effectiveness in patient care.

Ema offers a Universal AI employee designed to automate complex workflows and improve productivity within organizations. Utilizing the Generative Workflow Engine, Ema integrates seamlessly with enterprise applications, allowing users to delegate repetitive tasks efficiently. The platform combines multiple AI models to ensure accuracy and security, making it a valuable asset for various business functions such as customer support, HR, and finance.

Autobahn Therapeutics, Inc. is a biotechnology company based in San Diego, California, focused on developing small molecule therapies for central nervous system (CNS) disorders. Since its incorporation in 2017, Autobahn has aimed to address significant unmet needs in neuropsychiatry and neuroimmunology through its innovative brain-targeting chemistry platform. The company's leading candidate, ABX-002, is a thyroid hormone receptor beta agonist being investigated as a potential treatment for multiple sclerosis and adrenomyeloneuropathy, as well as an adjunctive therapy for major depressive disorder and bipolar disorder depression. Autobahn Therapeutics emphasizes precision tuning of CNS exposure, targeting validated clinical and biological markers to enhance therapeutic opportunities and patient outcomes.

Brightside Health, Inc. is a telemedicine platform that specializes in providing evidence-based treatments for anxiety and depression. Founded in 2017 and based in San Francisco, California, the company has developed a mobile application that offers personalized mental health care through video visits, messaging, and medication delivery. Its platform enables users to evaluate their mental health, access treatment and support, and communicate with healthcare providers for consultations and ongoing care. Brightside Health utilizes a care model that combines precision psychiatry with continuous monitoring, ensuring members receive effective treatment tailored to their needs. The company’s mission is to help individuals manage their mental health, leading to healthier and more productive lives.

Ema offers a Universal AI employee designed to automate complex workflows and improve productivity within organizations. Utilizing the Generative Workflow Engine, Ema integrates seamlessly with enterprise applications, allowing users to delegate repetitive tasks efficiently. The platform combines multiple AI models to ensure accuracy and security, making it a valuable asset for various business functions such as customer support, HR, and finance.

Freenome, Inc. is an artificial intelligence genomics biotech company based in South San Francisco, California, founded in 2014. The company focuses on developing accurate, accessible, and non-invasive blood tests for the early detection of cancer and treatment selection. Utilizing a proprietary multi-omics platform, Freenome employs advanced algorithms to analyze cell-free genomic data, which aids in identifying early-stage cancers and other diseases. This innovative approach aims to transform disease management by enabling timely interventions and proactive treatment strategies. In addition to its diagnostic solutions, Freenome also offers clinical research services to further advance cancer detection and management.

Pomelo is a fintech-as-a-service platform focused on providing innovative payment solutions in Latin America. The company has developed a digital processing platform designed to enhance payment services by allowing businesses to create virtual accounts and issue prepaid and credit cards. This is achieved through compliant onboarding processes, which facilitate the customization required by fintech companies and embedded finance players for their specific programs. By redefining the possibilities in payment services, Pomelo aims to support the growth and efficiency of financial technology in the region.

Puzzle Financial is a stealth mode SaaS startup focused on developing core accounting software designed to improve financial decision-making for startups. The platform aims to create a scalable foundation that supports fundraising, tax management, and real-time insights into overall business health. By transforming traditional accounting practices into a system of financial intelligence, Puzzle Financial enables startups to enhance their financial performance and gain greater trust and confidence in their financial operations.

ROME Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies for cancer and autoimmune diseases. Established in 2019, the company utilizes the repeatome—a previously overlooked segment of genetic material—to create novel treatment options. By identifying multiple drug targets and advancing several discovery programs, ROME Therapeutics aims to tap into this unexplored area of biology. The organization has assembled a team of experts in oncology, immunology, virology, and machine learning to lead its research and development efforts, which are designed to provide healthcare professionals with effective new treatments for patients suffering from these conditions.

Inceptive specializes in the design of RNA molecules through the integration of large-scale deep learning and high-throughput experiments. The company has developed a platform for biological software that facilitates the creation of synthetic molecules capable of performing complex biological functions. By focusing on the rational design of innovative medicines and biotechnologies, Inceptive aims to provide advancements in healthcare and biotechnology that were previously beyond reach.

Endor Labs specializes in enhancing application security by managing open-source software dependencies. The company provides a Dependency Lifecycle Management Platform designed to tackle vulnerabilities within the software supply chain, particularly the unmanaged proliferation of open-source software in enterprises. By streamlining the selection, security, and maintenance of software dependencies, Endor Labs aids developers in adopting safe open-source solutions, thereby accelerating development processes and reducing the time spent on security issues. The platform supports clients in maximizing code reuse and implementing microservices architectures, ultimately simplifying the complexities associated with software engineering.

Octave is a clinical platform developer focused on transforming the care landscape for multiple sclerosis and other neurodegenerative diseases. The company's platform generates, analyzes, and integrates data to provide a comprehensive approach aimed at reducing the overall cost of care. By optimizing healthcare medications and utilization, Octave enables pharmaceutical companies to enhance the entire lifecycle of drug discovery, clinical trials, and post-marketing processes through the use of real-world evidence. This innovative approach seeks to improve patient outcomes while streamlining healthcare practices.

AltPep Corp is a biomedical startup that specializes in diagnosing and treating amyloid diseases, which are known for their challenging nature. The company operates a proprietary peptide-based platform designed to identify and neutralize toxic precursors associated with these diseases. This innovative approach includes diagnostic and therapeutic applications, particularly focused on the early detection of toxic oligomers in Alzheimer's disease through a soluble oligomer binding assay. By enabling healthcare institutions to detect and address amyloid diseases at an earlier stage, AltPep aims to enhance human health outcomes and improve treatment options for patients suffering from these conditions.

Delve Bio is a biotechnology company focused on delivering molecular insights to enhance precision patient care. It specializes in the pathogen-agnostic and unbiased detection of neuro-infectious pathogens in cerebrospinal fluid (CSF). By providing comprehensive diagnostic solutions in a single test, Delve Bio equips laboratories and clinicians with critical information necessary for identifying both common and rare infectious diseases, thereby facilitating more accurate and timely medical interventions.

Function Oncology is a precision medicine company focused on developing advanced cancer therapies through a personalized functional genomics platform powered by CRISPR technology. This innovative platform allows for the identification of therapeutic opportunities tailored to individual patients, enhancing the understanding of cancer at a patient-specific level. By leveraging cutting-edge genomic tools, Function Oncology aims to transform targeted cancer treatment and create the next generation of therapies designed to meet the unique needs of each patient.

Faro Health is a developer of a cloud-based medical platform aimed at addressing the complexities of clinical trials. The platform standardizes, automates, and streamlines various challenges associated with clinical studies. By utilizing an integrated clinical development environment, Faro Health simplifies the design and authoring of complex clinical protocols. This system leverages advanced digital protocols to provide intuitive insights during the authoring process, allowing clinical researchers to focus on critical decisions that enhance clinical value while minimizing administrative burdens.

Forward Networks, Inc. is a software company based in Palo Alto, California, that specializes in network verification and automation. Founded in 2013, the company offers a platform that enhances network visibility, policy verification, and change modeling. This platform allows network teams to visualize and search complex networks effectively, enabling them to debug issues swiftly and verify the accuracy of network-wide policies. By providing a mathematically accurate representation of the network, Forward Networks aids engineers and operators in predicting network behavior before implementing changes, thereby reducing the likelihood of costly outages. The company also offers open-source tools like Beacon and Mininet to facilitate the management of data centers and software-defined networks.

MedCrypt Inc. is a cybersecurity company specializing in the protection of medical devices. Founded in 2016 and based in Encinitas, California, MedCrypt provides data security solutions for a wide range of medical devices, including implantable devices like pacemakers and various surgical robots. The company's platform offers data security as a service to medical device original equipment manufacturers (OEMs), enabling them to implement essential security features quickly and efficiently. These features include user authentication, data encryption, and transaction monitoring to detect potential malicious behavior. By integrating security capabilities into medical devices with minimal code, MedCrypt allows engineers to focus on developing innovative clinical functionalities while ensuring the safety and integrity of device operations.

Neocis, Inc. is a Miami-based company that specializes in robotic guidance systems for dental implant procedures. Founded in 2009, Neocis develops the Yomi system, a robotic device designed to enhance the precision of dental surgeries. Yomi integrates computer imagery from CT scans with surgical planning, providing dental surgeons with multi-sensory feedback during procedures. This technology aims to transform dental surgery by offering a minimally invasive approach, which can lead to faster recovery times for patients. The Yomi system has received clearance from the U.S. Food and Drug Administration and is commercially available in the United States, underscoring Neocis's commitment to advancing patient care and addressing the challenges faced by dental professionals.

Stairwell, Inc., founded in 2019 and headquartered in Mountain View, California, specializes in cybersecurity solutions through its Software as a Service (SaaS) platform. The company focuses on Automated Threat Detection and Response, providing tools that enable security teams to identify and address potential threats efficiently. By treating all files as suspicious and preserving them as evidence, Stairwell accelerates threat analysis, allowing organizations to quickly assess their security status in response to emerging threats. Its technology incorporates artificial intelligence and machine learning to deliver automated reports that indicate whether an organization has been compromised and, if so, outlines the details of the incident. This innovative approach enhances the capabilities of security personnel, streamlining the processes of threat evaluation and response. Stairwell has garnered recognition for its innovative contributions to the cybersecurity landscape, supported by prominent investors and partners.

Nested Therapeutics is a Cambridge-based biotech company founded in 2021, specializing in the development of precision oncology therapies. The firm focuses on discovering and creating small-molecule drugs that target specific cancer genes and driver mutations. By leveraging advanced techniques in genomics, computational chemistry, proteomics, and artificial intelligence, Nested Therapeutics aims to identify druggable pockets within mutation clusters. This approach allows for the development of novel therapies that enable healthcare professionals to provide more effective and targeted treatments for cancer patients.

Autobahn Therapeutics, Inc. is a biotechnology company based in San Diego, California, focused on developing small molecule therapies for central nervous system (CNS) disorders. Since its incorporation in 2017, Autobahn has aimed to address significant unmet needs in neuropsychiatry and neuroimmunology through its innovative brain-targeting chemistry platform. The company's leading candidate, ABX-002, is a thyroid hormone receptor beta agonist being investigated as a potential treatment for multiple sclerosis and adrenomyeloneuropathy, as well as an adjunctive therapy for major depressive disorder and bipolar disorder depression. Autobahn Therapeutics emphasizes precision tuning of CNS exposure, targeting validated clinical and biological markers to enhance therapeutic opportunities and patient outcomes.

Spectral is a New Rochelle, New York-based company founded in 2020 that focuses on programmable creditworthiness through its innovative platform. The company provides valuable credit risk insights to its partners by utilizing on-chain data, thereby enhancing business decisions and offerings. Users can access new financial opportunities through the Multi-Asset Credit Risk Oracle (MACRO) Score, which serves as an on-chain equivalent to a traditional FICO score, allowing individuals to check their on-chain credit scores. Additionally, Spectral offers an AI-powered platform that simplifies the creation and deployment of smart contracts, enabling developers to generate complex contracts using natural language, thus accelerating development time and minimizing errors.

Inworld AI is an AI framework powering massive consumer applications. Inworld is funded by VCs including Lightspeed, Stanford University, Kleiner Perkins, Founders Fund, Section 32, M12, Intel Capital, CRV, Bitkraft, and Meta, as well as a team of all-star angels including corporate executives, top VC funds' partners, scouts, and industry veterans.

Pomelo is a fintech-as-a-service platform focused on providing innovative payment solutions in Latin America. The company has developed a digital processing platform designed to enhance payment services by allowing businesses to create virtual accounts and issue prepaid and credit cards. This is achieved through compliant onboarding processes, which facilitate the customization required by fintech companies and embedded finance players for their specific programs. By redefining the possibilities in payment services, Pomelo aims to support the growth and efficiency of financial technology in the region.

BigHat Biosciences, Inc. is a biotechnology company based in San Carlos, California, founded in 2019. The company specializes in developing an automated platform that combines a wet laboratory with artificial intelligence and machine learning techniques for the production and characterization of antibodies. This innovative platform empowers drug developers to engineer antibodies and other therapeutic proteins with improved biophysical properties and complex functions. By leveraging AI-guided design capabilities, BigHat aims to create safer and more effective treatments for patients facing challenging diseases, thereby advancing the field of biotherapeutics.

Phaidra, Inc. is an AI solutions provider based in Seattle, Washington, founded in 2019. The company specializes in developing artificial intelligence-powered control systems tailored for large industrial facilities. Phaidra's technology analyzes vast amounts of sensor data to create intelligent agents that optimize complex operations. This virtual plant operator enhances the performance of mission-critical facilities by improving energy efficiency, stability, and sustainability. Through its closed-loop AI control service, Phaidra enables operations teams to achieve significant operational improvements, thereby maximizing yield and enhancing safety within industrial environments.

Swadesh is a digital banking platform designed for the Indian diaspora, facilitating seamless financial management for customers residing abroad. The platform enables users to open bank accounts, invest, remit funds, and manage their finances in India with ease. By focusing on the unique needs of the Indian community overseas, Swadesh aims to provide a user-friendly experience that simplifies investing and money management across borders.

Manifold Biotechnologies, Inc. is a biotechnology company that specializes in developing platforms for the pharmacological measurement of various therapeutic protein variants. By integrating DNA technologies with machine learning, the company aims to create protein drugs that address challenging diseases. Manifold Bio's innovative approach includes a protein barcoding platform designed to enable multiplexed quantitation of protein therapeutics, thereby generating extensive data that enhances the drug development process. Founded in 2019 and located in Allston, Massachusetts, the company is focused on advancing measurement-driven design in the field of protein therapeutics.

Character Therapeutics is a patient-driven therapeutics company that uses genomics, longitudinal clinical and imaging data, machine learning, and novel experimental approaches to identify the molecular drivers of disease progression and develop innovative targeted medicines. Its dedication to patients is reflected in the high standards set to ensure privacy, data security, ethics, scientific rigor, and a meaningful impact on patient health. To enable clinical genomic research, the company collaborates with patients, providers, payers, and scientists to create deeply phenotyped patient cohorts.

Legacy is a company focused on transforming male fertility through innovative testing and preservation solutions. Founded by healthcare and fertility experts, Legacy provides home-based kits that allow men to analyze, improve, and preserve their sperm without the need to visit a clinic. Their offerings include sperm analysis and cryogenic storage options, facilitating the preservation of fertility for clients in a straightforward and accessible manner. The company collaborates with leading hospitals, fertility clinics, and progressive employers to ensure high-quality services. Legacy has garnered recognition through various awards, including victories at TechCrunch Disrupt and MassChallenge Boston, and has attracted investment from notable firms such as Bain Capital Ventures and Section 32.

MOMA Therapeutics is a biotechnology company based in Cambridge, Massachusetts, founded in 2019. The company focuses on discovering precision medicines by targeting molecular machines that are fundamental to human disease. MOMA Therapeutics utilizes a unique platform that leverages the common features of the ATPase target class, which includes significant conformational changes and energy-driven mechanics. By combining these insights with advancements in structural biology and small-molecule drug discovery, MOMA Therapeutics aims to develop drugs targeting previously challenging enzymes, contributing to the next generation of targeted therapies. The company was formerly known as ATPases NewCo, Inc. before rebranding in March 2020.

Aspen Neuroscience, Inc. is a biotechnology company focused on developing induced pluripotent stem cells (iPSCs) to create patient-specific therapies for neurological conditions, particularly Parkinson's disease. Founded in 2018 and based in San Diego, California, the company is advancing its pipeline of products, which includes ANPD001, an autologous neuron replacement therapy for sporadic Parkinson's disease, and ANPD002, a gene-edited autologous neuron replacement therapy targeting familial forms of the disease. Aspen Neuroscience employs innovative genomic approaches in conjunction with stem cell biology to address diseases with significant unmet medical needs, aiming to provide restorative cell therapies that can modify the progression of Parkinson's disease and potentially extend to other affected organs.

Nirvana is an AI-native financial infrastructure shaping the future of Agentic DeFi. - Redefining DeFi with AI Agents – Nirvana builds AI frameworks for DEFAI agents to maximize capital efficiency - AI-Native On-Chain Protocols – Empowering DEFAI agents with AI-native protocols to autonomously launch innovative financial instruments and optimize strategies

Celsius Therapeutics is a biotechnology company focused on developing precision medicines for patients with cancer and autoimmune diseases. Founded in 2018 and based in Cambridge, Massachusetts, the company employs a team of scientists, technologists, computational biologists, clinicians, and drug hunters. Utilizing single-cell genomic analysis and machine learning techniques, Celsius Therapeutics aims to discover and create innovative therapies that can lead to significant improvements in patient outcomes. The company's research efforts are centered on identifying new drug candidates that address unmet medical needs in the therapeutic landscape.

Nucleai Ltd. is a spatial biology company that has developed an AI-powered pathology platform focused on enhancing drug development and improving patient outcomes. Founded in 2017 and headquartered in Tel Aviv-Yafo, Israel, Nucleai's technology utilizes unique tissue datasets and machine learning algorithms to analyze biopsy samples and detect various cancers, including prostate, breast, and gastrointestinal diseases. The platform aims to improve the interpretation of pathology results, thereby increasing the efficacy of clinical trials and fostering better patient care. Nucleai collaborates with leading pharmaceutical companies, licensing its platform for internal use and participating in biomarker discovery projects. By transforming healthcare through artificial intelligence, Nucleai strives to enable researchers to identify novel biomarkers that predict therapeutic responses and enhance understanding of complex biological phenomena.

SandboxAQ is a company that develops artificial intelligence and quantum technology solutions aimed at addressing complex business and scientific challenges. By integrating expertise from multiple disciplines, including physics, computer science, and mathematics, the company creates Large Quantitative Models and AI sensing applications tailored for various industries. Its offerings are designed to provide practical solutions in sectors such as financial services, healthcare, telecommunications, and cybersecurity. Through its innovative software, SandboxAQ enables clients to tackle significant computational challenges and advance their technological capabilities.

Satellite Bio is a company that specializes in cell therapy, regenerative medicine, synthetic biology, cell biology, and tissue engineering. It is dedicated to developing a therapeutic platform aimed at creating innovative cell therapies to address complex diseases. The company’s primary focus is on the design and implementation of proprietary, off-the-shelf, implantable satellite organs, which serve as living therapeutic solutions. These satellite organs are intended to improve the lives of millions of patients suffering from serious health conditions.

Cohere is a technology company that specializes in natural language processing (NLP) software, designed to enhance the ability of machines to understand human language. By leveraging advanced large language models, Cohere provides developers and businesses with tools that enable them to create applications capable of interpreting meaning, sentiment, and tone from text. This capability not only improves comprehension but also facilitates the development of more personalized user experiences. The company's focus is on making these sophisticated language models safely accessible, ensuring that organizations can harness the power of NLP to better engage with their users and derive insights from vast amounts of textual data.

Syllable is a technology company that develops a platform designed to enhance communication between patients and healthcare providers through text and voice interactions. The platform enables patients to access vital healthcare information regarding primary care, specialty referrals, vaccinations, and general practice, facilitating guidance outside of traditional clinical settings. Additionally, Syllable focuses on building AI agents and managing AI operations, integrating tools and services from third-party providers of large language models and AI technologies, which further supports its mission to improve patient-provider communication.

Metaphysic is a developer of software focused on the creation of synthetic media, aiming to enhance human expression through ethical applications. The company's technology reconstructs low-resolution video footage and generates realistic facial representations, allowing users to edit expressions and facial features seamlessly. This innovative approach enables content creators to produce immersive and realistic experiences in various media, particularly within the metaverse. By leveraging artificial intelligence, Metaphysic provides tools that expand the creative possibilities for artists and filmmakers, ensuring a natural and engaging interaction with digital content.

ONI is a leader in super-resolution microscopy, offering innovative tools that enhance biological research. The company has developed the Nanoimager, the first benchtop super-resolution microscope, which provides unprecedented usability and precision for researchers. This device enables access to various super-resolution techniques, including dSTORM, PALM, smFRET, and single-particle tracking, facilitating a deeper understanding of cellular structures and functions. ONI's products are increasingly adopted by academic researchers and pharmaceutical companies, with installations in prominent laboratories such as those at the Universities of Oxford, Cambridge, and Harvard. The company's mission is to democratize scientific discovery by making advanced imaging technology more accessible and affordable, thereby empowering researchers to visualize and share the intricate details of life. Recognized for its innovative contributions, ONI has received accolades such as being named a Disruptor to Watch and winning Best Business Start-up at the IOP Awards. Through its commitment to advancing scientific research, ONI aims to accelerate discoveries that can lead to improved health outcomes.

Nodexus is a biotech startup focused on providing innovative solutions for live single-cell isolation through its NX One platform. This platform features a low-cost, low-infrastructure hardware system paired with single-use disposable microfluidic cartridges, facilitating various applications in the biopharma, clinical research, and academic fields. Nodexus's technology supports critical workflows such as gene editing, cell line and antibody development, and studies of tumor heterogeneity. By offering affordable automated cell isolation, Nodexus aims to enhance biological research and development, making advanced methodologies more accessible to a wider range of clients.

Dialpad, Inc. is a cloud-based communications platform that specializes in enterprise solutions, offering a comprehensive suite of services including voice, video, group messaging, SMS, MMS, conferencing, and sharing of screens and documents. Founded in 2002 and based in San Francisco, the company has transformed its offerings through AI-powered features such as real-time transcription, automated note-taking, live sentiment analysis, and voice analytics. Dialpad's products, which include Dialpad, Dialpad Sell, UberConference, and Dialpad Contact Center, are designed to enhance collaboration and communication for businesses, enabling employees to work securely from any location and device. The company serves notable clients such as Motorola Solutions, ClassPass, Warby Parker, and Vivint, and has strategic partnerships with industry leaders like SoftBank Corp. Dialpad was previously known as Switch Communications, Inc. before rebranding in 2016.

Verge Genomics is a biotechnology company focused on transforming drug discovery for neurodegenerative diseases through the application of artificial intelligence. Founded by experts in machine learning and seasoned drug developers in neuroscience, the company aims to leverage advances in computational genomics and insights into brain science to identify promising therapeutic targets. Its drug discovery platform utilizes machine learning algorithms to analyze large datasets, enabling the identification of effective drugs and accelerating the development of life-saving treatments. By improving the efficiency of the drug development process, Verge Genomics seeks to enhance patient outcomes and reduce the overall costs associated with pharmaceutical development.

Exai Bio is a next-generation liquid biopsy company that specializes in the early and accurate diagnosis of cancer. The company has developed a proprietary platform that analyzes cell-free RNA profiles, utilizing advanced artificial intelligence and machine learning algorithms. This technology focuses on orphan non-coding RNA and small RNA sequences that are prevalent in tumors but absent in normal tissue. By delivering clinical insights into cancer biology, Exai Bio's platform aids healthcare professionals in identifying cancer at its earliest stages and informs personalized treatment options for patients.

Freenome, Inc. is an artificial intelligence genomics biotech company based in South San Francisco, California, founded in 2014. The company focuses on developing accurate, accessible, and non-invasive blood tests for the early detection of cancer and treatment selection. Utilizing a proprietary multi-omics platform, Freenome employs advanced algorithms to analyze cell-free genomic data, which aids in identifying early-stage cancers and other diseases. This innovative approach aims to transform disease management by enabling timely interventions and proactive treatment strategies. In addition to its diagnostic solutions, Freenome also offers clinical research services to further advance cancer detection and management.

MedArrive, Inc. operates a software-as-a-service health platform that facilitates the extension of healthcare services into patients' homes. Based in New York, the company connects healthcare providers with a network of emergency medical professionals, allowing for a seamless integration of in-home care and telemedicine. This innovative approach aims to serve vulnerable populations by improving access to high-quality healthcare while reducing overall costs. MedArrive's platform consolidates clinical data into electronic medical records and enhances communication and billing processes, ultimately fostering better patient outcomes and encouraging self-advocacy among patients. By utilizing an underemployed workforce, MedArrive aims to bridge the virtual care gap, ensuring continuity of care and re-engaging patients in primary healthcare services.

Mekonos Inc. specializes in the design, development, and production of gene and cell therapies, focusing on a proprietary cell-engineering platform that utilizes advanced silicon technology. Founded in 2017 and based in San Francisco, the company has created an integrated system-on-a-chip, which incorporates micro-electromechanical systems (MEMS) to enable the precise injection of single cells using nanoneedles in a parallel architecture. This innovative approach aims to industrialize genome editing and enhance drug discovery and development processes. Mekonos' technology allows for scalable and reliable manufacturing of engineered therapies aimed at addressing genetic diseases, including various forms of cancer, and supports healthcare providers in delivering diverse therapeutic molecules across multiple cell types.

Arbor Biotechnologies, Inc., founded in 2016 and headquartered in Cambridge, Massachusetts, operates as a bio-discovery company in the biotechnology sector. The company focuses on developing genomic tools that enhance human health and sustainability. Utilizing a combination of artificial intelligence, genome sequencing, gene synthesis, and high-throughput screening, Arbor's platform accelerates the discovery of proteins and facilitates human diagnostic development. The technology aggregates genomic sequence data through AI and machine learning, enabling drug developers to replace entire genes and precisely correct mutations. This approach aims to streamline the development of curative treatments for previously incurable genetic diseases, ultimately improving the lives of patients affected by such conditions.

Parthenon Therapeutics is inventing a novel class of anti-cancer therapies that reprogram the tumor microenvironment (TME). The interplay between cancer cells and their surrounding microenvironment is relevant in drug development as manycancers use the TME to build barriers that shield immune system attack. One approach, PRTH-101, breaks these barriers to overcome recalcitrant cancers. Based on research, the company is designing a portfolio of drug candidates to treat the right patients at the right time.

Culture Biosciences, Inc. is a biomanufacturing company based in South San Francisco, California, that offers a cloud-based platform for scientists to conduct, monitor, and analyze bioreactor experiments. Founded in 2016, the company focuses on automating bioprocesses to help biotech firms optimize their manufacturing processes and expedite product development. By utilizing robotic sample handling and cloud data monitoring, Culture Biosciences enhances the efficiency of fermentation and bioreactor operations, allowing researchers to achieve results more rapidly than with traditional methods.

ScienceIO is a biomedical language platform founded in 2019 by Gaurav Kaushik and Will Manidis in Massachusetts, United States. The company specializes in transforming unstructured biomedical data into usable and contextualized information. Its platform detects and extracts biomedical terms, clinical variables, and medical codes from complex medical texts, enabling the conversion of intricate information into actionable insights. By linking medical concepts, ScienceIO facilitates powerful queries, providing clients with easy access to relevant medical alternatives through the decoding of medical data.

Gretel.ai is a San Diego-based company founded in 2019 that specializes in a multimodal synthetic data platform. The platform employs advanced generative AI and privacy-enhancing technologies to create artificial datasets that mimic the characteristics of real data. This allows developers to generate, test, and refine AI models without compromising individual privacy. Gretel's technology includes automatic data categorization and identification, enabling seamless labeling of customer identifiers such as names and addresses. By providing a secure environment for experimenting with customer data, Gretel facilitates collaboration among developers while ensuring compliance with privacy standards.

Wise Systems Inc. develops autonomous dispatch and routing software that enhances delivery efficiency for various industries, including food, beverage, courier, energy, and field service. Founded in 2014 and based in Cambridge, Massachusetts, the company leverages machine learning algorithms to optimize last-mile operations. Its platform includes tools such as Scheduler, which dynamically creates and dispatches optimized route plans; Dispatcher, which allows managers to monitor delivery progress and driver performance; and Customer Portal, enabling recipients to track their orders with real-time ETAs. Wise Systems also offers Smart Reservation Management, allowing customers to select their preferred delivery times. Clients typically experience significant benefits, including reductions in mileage and late deliveries, as well as increased fleet utilization. The software processes millions of data points to make real-time decisions, facilitating efficient transportation operations while reducing costs.

Formation Bio is a biotechnology company dedicated to accelerating drug development and enhancing patient access to new treatments by reimagining clinical trials. The company has developed a platform that scales a network of clinical trial sites integrated within existing medical practices. By utilizing a roaming cohort of certified research coordinators and leveraging advanced software and data analytics, Formation Bio enables researchers to optimize their access to human subjects for various studies, including clinical trials and psychological research. This innovative approach aims to streamline the clinical trial process, ultimately facilitating faster delivery of new therapies to patients.

ROME Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies for cancer and autoimmune diseases. Established in 2019, the company utilizes the repeatome—a previously overlooked segment of genetic material—to create novel treatment options. By identifying multiple drug targets and advancing several discovery programs, ROME Therapeutics aims to tap into this unexplored area of biology. The organization has assembled a team of experts in oncology, immunology, virology, and machine learning to lead its research and development efforts, which are designed to provide healthcare professionals with effective new treatments for patients suffering from these conditions.

Cohere is a technology company that specializes in natural language processing (NLP) software, designed to enhance the ability of machines to understand human language. By leveraging advanced large language models, Cohere provides developers and businesses with tools that enable them to create applications capable of interpreting meaning, sentiment, and tone from text. This capability not only improves comprehension but also facilitates the development of more personalized user experiences. The company's focus is on making these sophisticated language models safely accessible, ensuring that organizations can harness the power of NLP to better engage with their users and derive insights from vast amounts of textual data.

Syllable is a technology company that develops a platform designed to enhance communication between patients and healthcare providers through text and voice interactions. The platform enables patients to access vital healthcare information regarding primary care, specialty referrals, vaccinations, and general practice, facilitating guidance outside of traditional clinical settings. Additionally, Syllable focuses on building AI agents and managing AI operations, integrating tools and services from third-party providers of large language models and AI technologies, which further supports its mission to improve patient-provider communication.

ImmuneID is a precision immunology company that has developed a proprietary platform aimed at identifying and therapeutically targeting antibody interactions involved in immune diseases. The platform utilizes advanced methodologies, including massively parallel, multiplexed, and unbiased systems, to facilitate the development of therapeutics for various conditions such as autoimmunity, severe allergies, oncology, and infectious diseases. By enabling researchers to observe and analyze human immune responses across different stages of disease progression, ImmuneID seeks to enhance the understanding of immune mechanisms and improve treatment strategies.

Primer Technologies, Inc., established in 2014 and headquartered in San Francisco, specializes in developing software that leverages machine learning and natural language processing to analyze vast amounts of textual data across multiple languages. Its platform automates the parsing and collation of documents, uncovering insights and generating reports comparable to those produced by human analysts. This enables governments and corporations to better understand and monitor global information, facilitating informed decision-making.

Faro Health is a developer of a cloud-based medical platform aimed at addressing the complexities of clinical trials. The platform standardizes, automates, and streamlines various challenges associated with clinical studies. By utilizing an integrated clinical development environment, Faro Health simplifies the design and authoring of complex clinical protocols. This system leverages advanced digital protocols to provide intuitive insights during the authoring process, allowing clinical researchers to focus on critical decisions that enhance clinical value while minimizing administrative burdens.

Phaidra, Inc. is an AI solutions provider based in Seattle, Washington, founded in 2019. The company specializes in developing artificial intelligence-powered control systems tailored for large industrial facilities. Phaidra's technology analyzes vast amounts of sensor data to create intelligent agents that optimize complex operations. This virtual plant operator enhances the performance of mission-critical facilities by improving energy efficiency, stability, and sustainability. Through its closed-loop AI control service, Phaidra enables operations teams to achieve significant operational improvements, thereby maximizing yield and enhancing safety within industrial environments.

Singular Genomics is a life science technology company focused on advancing next generation sequencing (NGS) and multiomics technologies to support researchers and clinicians. The company's core platform, the Singular Sequencing Engine, underpins its product offerings, emphasizing accuracy, speed, flexibility, and scalability. Singular Genomics has developed two primary integrated solutions: the G4 Integrated Solution, which targets the NGS market with a combination of instrument and consumable kits, and the PX Integrated Solution, which integrates single cell analysis, spatial analysis, genomics, and proteomics into a versatile platform. These solutions cater to various market segments, including basic biology, oncology, and immunology, enhancing research capabilities across diverse applications.

TwinStrand Biosciences specializes in advanced DNA sequencing technologies, significantly enhancing the accuracy of mutation detection beyond conventional methods. Their proprietary Duplex Sequencing technology enables the identification of mutations that are often undetectable by standard approaches, making it valuable in various fields such as oncology, infectious disease, organ transplantation, reproductive and genetic health, and forensics. The company is dedicated to improving diagnostic capabilities and advancing research through its innovative sequencing solutions. TwinStrand is also involved in biopharmaceutical development, focusing on the discovery and commercialization of biological drugs aimed at treating life-threatening diseases, particularly cancers. Their product pipeline includes recombinant protein-based prodrugs designed for activation by matrix metalloproteinases associated with solid tumors.

Current Health Limited, founded in 2014 and based in Edinburgh, United Kingdom, specializes in developing wearable healthcare devices that monitor patients' vital signs. These devices are designed to measure key health metrics such as oxygen saturation, respiration rate, pulse rate, temperature, motion, activity, and posture, allowing for the early identification of unwell patients and timely medical intervention. The company also offers a patient monitoring platform that facilitates home-based care by enabling patients to share daily activities, report symptoms, and respond to structured questionnaires for their healthcare providers. By focusing on remote patient management, Current Health aims to reduce healthcare risks and costs while enhancing patient engagement and monitoring. Formerly known as Snap40 Limited, the company rebranded in December 2018 to better reflect its mission.

C2i Genomics, Inc. specializes in whole genome analysis solutions aimed at monitoring tumor recurrence in post-surgery cancer patients. The company offers liquid biopsy services that analyze subtle changes in tumor DNA to provide insights into cancer progression and recurrence. This technology enables the development of a bio-platform approach applicable across various cancer types, facilitating the guidance of diverse treatment modalities, including surgery, chemotherapy, immunotherapy, and targeted therapies. Additionally, C2i Genomics provides cloud-based cancer diagnostic services to pharmaceutical and diagnostic organizations, enhancing the ability of healthcare providers to monitor treatment responses and detect recurrences or failures earlier than traditional methods allow. Founded in 2019 and headquartered in New York, with a research and development center in Haifa, Israel, C2i Genomics aims to improve the lives and outcomes of cancer patients through innovative diagnostic solutions.

Meatable is a food production company specializing in the creation of cultured meat through advanced stem cell technology. By utilizing pluripotent stem cells, which can differentiate into various cell types such as muscle and fat without the need for serum, Meatable's innovative approach allows for the production of meat without extracting tissue from animals. This method not only promotes sustainability but also offers consumers a guilt-free alternative to traditional meat. The company's focus on efficient and responsible food production positions it as a leader in the emerging market for lab-grown meat.

Miroculus, Inc. is a biotechnology company specializing in non-invasive molecular data gathering and analysis solutions. Founded in 2014 and based in San Francisco, California, Miroculus develops advanced digital microfluidic technology that automates and miniaturizes genomic protocols, such as next-generation sequencing library preparation, cell editing, and synthetic biology. The company's hands-off sample-to-answer platform provides assay flexibility and integrates seamlessly into existing workflows, enabling the detection and monitoring of diseases at the molecular level. Miroculus serves a wide range of clients, including academic institutions, genomic research centers, pharmaceuticals, biotechnology firms, and diagnostic companies, offering low-cost, accurate, and minimally invasive molecular testing tools with its proprietary cartridge-based system.

EQRx, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on transforming the drug discovery and delivery process to address the rising costs of medicines. Founded in 2019, EQRx aims to provide a market-based solution by leveraging advances in science and technology while collaborating with various healthcare stakeholders. The company has over ten programs in its pipeline targeting oncology and immune-inflammatory conditions, which include clinical and preclinical stages, as well as drug engineering initiatives. Among its key programs are Aumolertinib, Lerociclib, Sugemalimab, and Nofazinlimab. Through its innovative approach, EQRx seeks to develop high-quality, patent-protected medicines more efficiently and cost-effectively than traditional pharmaceutical methods.

Octave is a clinical platform developer focused on transforming the care landscape for multiple sclerosis and other neurodegenerative diseases. The company's platform generates, analyzes, and integrates data to provide a comprehensive approach aimed at reducing the overall cost of care. By optimizing healthcare medications and utilization, Octave enables pharmaceutical companies to enhance the entire lifecycle of drug discovery, clinical trials, and post-marketing processes through the use of real-world evidence. This innovative approach seeks to improve patient outcomes while streamlining healthcare practices.

WithMe Health, LLC is a medication guidance company founded in 2018 and based in San Mateo, California. The company focuses on providing personalized medication guidance solutions that enhance the medication experience for employees and their families. By replacing traditional pharmacy benefit managers, WithMe Health offers a more comprehensive service that leverages modern technology and extensive datasets to tailor medication selection to individual needs. Their innovative approach emphasizes proactive and adaptive care, ensuring that members receive support at every step of their medication journey. This model not only optimizes health outcomes but also aims to reduce costs for employers, aligning the interests of all stakeholders in the pharmaceutical value chain.

Vineti, Inc. is a technology company that specializes in developing solutions for the therapeutic delivery of personalized medicine, particularly focusing on cell and gene therapies. Founded in 2016 and headquartered in San Francisco, California, with additional offices in Bethesda, Maryland, and Yerevan, Armenia, Vineti offers a cloud-based platform known as the Personalized Therapy Management (PTM) platform. This platform streamlines and automates patient-centric supply chains, facilitating the efficient management of operations, manufacturing, quality control, and regulatory compliance for advanced therapies, including CAR-T cell therapies for late-stage cancer. Vineti's solutions aim to enhance patient access to life-saving treatments while addressing the challenges faced by patients, healthcare providers, pharmaceutical companies, and regulators in the commercialization of personalized medicine. By providing tools for supply chain orchestration and maintaining an audit trail for the handling of cell products, Vineti positions itself as a critical player in the evolving landscape of personalized therapeutics.

Neocis, Inc. is a Miami-based company that specializes in robotic guidance systems for dental implant procedures. Founded in 2009, Neocis develops the Yomi system, a robotic device designed to enhance the precision of dental surgeries. Yomi integrates computer imagery from CT scans with surgical planning, providing dental surgeons with multi-sensory feedback during procedures. This technology aims to transform dental surgery by offering a minimally invasive approach, which can lead to faster recovery times for patients. The Yomi system has received clearance from the U.S. Food and Drug Administration and is commercially available in the United States, underscoring Neocis's commitment to advancing patient care and addressing the challenges faced by dental professionals.

Dialpad, Inc. is a cloud-based communications platform that specializes in enterprise solutions, offering a comprehensive suite of services including voice, video, group messaging, SMS, MMS, conferencing, and sharing of screens and documents. Founded in 2002 and based in San Francisco, the company has transformed its offerings through AI-powered features such as real-time transcription, automated note-taking, live sentiment analysis, and voice analytics. Dialpad's products, which include Dialpad, Dialpad Sell, UberConference, and Dialpad Contact Center, are designed to enhance collaboration and communication for businesses, enabling employees to work securely from any location and device. The company serves notable clients such as Motorola Solutions, ClassPass, Warby Parker, and Vivint, and has strategic partnerships with industry leaders like SoftBank Corp. Dialpad was previously known as Switch Communications, Inc. before rebranding in 2016.

Freenome, Inc. is an artificial intelligence genomics biotech company based in South San Francisco, California, founded in 2014. The company focuses on developing accurate, accessible, and non-invasive blood tests for the early detection of cancer and treatment selection. Utilizing a proprietary multi-omics platform, Freenome employs advanced algorithms to analyze cell-free genomic data, which aids in identifying early-stage cancers and other diseases. This innovative approach aims to transform disease management by enabling timely interventions and proactive treatment strategies. In addition to its diagnostic solutions, Freenome also offers clinical research services to further advance cancer detection and management.

GeneDx is a company dedicated to providing personalized and actionable health insights that enhance diagnosis and treatment, ultimately improving health outcomes. Positioned at the intersection of diagnostics and data science, GeneDx combines decades of genomic expertise with the capability to interpret clinical data at scale. The company focuses on accelerating the application of genomic information and large-scale clinical data to establish precision medicine as a standard practice in healthcare. GeneDx leads the transformation of healthcare through its comprehensive exome and genome testing services, leveraging one of the largest rare disease data sets in the world. The business operates through two segments: GeneDx, which generates the majority of its revenue, and Legacy Sema4 diagnostics.

Thrive Earlier Detection Corp. is a healthcare company that specializes in developing advanced blood testing technologies for early cancer detection. Its flagship product, CancerSEEK, is a liquid biopsy test that analyzes genomic mutations in tumor DNA and protein markers in plasma, allowing for the identification of various cancers at their nascent stages, often before symptoms manifest. Founded in 2018 and headquartered in Cambridge, Massachusetts, with an additional office in Baltimore, Maryland, Thrive aims to integrate cancer screening into standard medical practice. The company leverages real-world data and machine learning to enhance the accuracy of cancer detection, facilitate follow-up testing, and streamline the transition to oncological care. Thrive operates as a subsidiary of Exact Sciences Corporation and has received investments from notable firms including Third Rock Ventures and Section 32.

Glympse Bio, Inc. is a diagnostic company based in Cambridge, Massachusetts, that focuses on developing modular nanoparticle sensors for noninvasive disease monitoring. Founded in 2015, the company creates engineered diagnostic agents designed to interrogate the body for specific disease states, subsequently conveying this information through urine analysis. This innovative approach facilitates the monitoring of various conditions, including fibrosis, cancer, immunology, and infectious diseases, while also assessing drug responses. Glympse Bio's flagship product, Glympse Inside, serves as a pan-disease platform aimed at revolutionizing how diseases are monitored and treated. The technology was initially developed at MIT and is supported by a team of experts in nanomedicine and biomedical engineering.

Evidation Health, Inc. specializes in developing digital tools and technologies for healthcare data analytics. The company connects digital health firms with healthcare providers and payers through its advanced platform, which transforms everyday behavior data from various sources, including sensors and devices, into actionable insights regarding health and disease. Its products include a Data Platform that analyzes this high-frequency behavior data and a technology-enabled service called Studies, which facilitates real-world research to support clinical and commercial efforts. By focusing on the interplay between everyday behaviors and health outcomes, Evidation aims to empower individuals and healthcare companies to improve health management outside traditional clinical settings. Founded in 2012 and headquartered in San Mateo, California, the company also operates additional offices in San Francisco and Santa Barbara.

Autobahn Therapeutics, Inc. is a biotechnology company based in San Diego, California, focused on developing small molecule therapies for central nervous system (CNS) disorders. Since its incorporation in 2017, Autobahn has aimed to address significant unmet needs in neuropsychiatry and neuroimmunology through its innovative brain-targeting chemistry platform. The company's leading candidate, ABX-002, is a thyroid hormone receptor beta agonist being investigated as a potential treatment for multiple sclerosis and adrenomyeloneuropathy, as well as an adjunctive therapy for major depressive disorder and bipolar disorder depression. Autobahn Therapeutics emphasizes precision tuning of CNS exposure, targeting validated clinical and biological markers to enhance therapeutic opportunities and patient outcomes.

Phaidra, Inc. is an AI solutions provider based in Seattle, Washington, founded in 2019. The company specializes in developing artificial intelligence-powered control systems tailored for large industrial facilities. Phaidra's technology analyzes vast amounts of sensor data to create intelligent agents that optimize complex operations. This virtual plant operator enhances the performance of mission-critical facilities by improving energy efficiency, stability, and sustainability. Through its closed-loop AI control service, Phaidra enables operations teams to achieve significant operational improvements, thereby maximizing yield and enhancing safety within industrial environments.

Aspen Neuroscience, Inc. is a biotechnology company focused on developing induced pluripotent stem cells (iPSCs) to create patient-specific therapies for neurological conditions, particularly Parkinson's disease. Founded in 2018 and based in San Diego, California, the company is advancing its pipeline of products, which includes ANPD001, an autologous neuron replacement therapy for sporadic Parkinson's disease, and ANPD002, a gene-edited autologous neuron replacement therapy targeting familial forms of the disease. Aspen Neuroscience employs innovative genomic approaches in conjunction with stem cell biology to address diseases with significant unmet medical needs, aiming to provide restorative cell therapies that can modify the progression of Parkinson's disease and potentially extend to other affected organs.

Culture Biosciences, Inc. is a biomanufacturing company based in South San Francisco, California, that offers a cloud-based platform for scientists to conduct, monitor, and analyze bioreactor experiments. Founded in 2016, the company focuses on automating bioprocesses to help biotech firms optimize their manufacturing processes and expedite product development. By utilizing robotic sample handling and cloud data monitoring, Culture Biosciences enhances the efficiency of fermentation and bioreactor operations, allowing researchers to achieve results more rapidly than with traditional methods.

Vineti, Inc. is a technology company that specializes in developing solutions for the therapeutic delivery of personalized medicine, particularly focusing on cell and gene therapies. Founded in 2016 and headquartered in San Francisco, California, with additional offices in Bethesda, Maryland, and Yerevan, Armenia, Vineti offers a cloud-based platform known as the Personalized Therapy Management (PTM) platform. This platform streamlines and automates patient-centric supply chains, facilitating the efficient management of operations, manufacturing, quality control, and regulatory compliance for advanced therapies, including CAR-T cell therapies for late-stage cancer. Vineti's solutions aim to enhance patient access to life-saving treatments while addressing the challenges faced by patients, healthcare providers, pharmaceutical companies, and regulators in the commercialization of personalized medicine. By providing tools for supply chain orchestration and maintaining an audit trail for the handling of cell products, Vineti positions itself as a critical player in the evolving landscape of personalized therapeutics.

Legacy is a company focused on transforming male fertility through innovative testing and preservation solutions. Founded by healthcare and fertility experts, Legacy provides home-based kits that allow men to analyze, improve, and preserve their sperm without the need to visit a clinic. Their offerings include sperm analysis and cryogenic storage options, facilitating the preservation of fertility for clients in a straightforward and accessible manner. The company collaborates with leading hospitals, fertility clinics, and progressive employers to ensure high-quality services. Legacy has garnered recognition through various awards, including victories at TechCrunch Disrupt and MassChallenge Boston, and has attracted investment from notable firms such as Bain Capital Ventures and Section 32.

EQRx, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on transforming the drug discovery and delivery process to address the rising costs of medicines. Founded in 2019, EQRx aims to provide a market-based solution by leveraging advances in science and technology while collaborating with various healthcare stakeholders. The company has over ten programs in its pipeline targeting oncology and immune-inflammatory conditions, which include clinical and preclinical stages, as well as drug engineering initiatives. Among its key programs are Aumolertinib, Lerociclib, Sugemalimab, and Nofazinlimab. Through its innovative approach, EQRx seeks to develop high-quality, patent-protected medicines more efficiently and cost-effectively than traditional pharmaceutical methods.

XOKind Inc. is an artificial intelligence software company based in San Diego, California, founded in 2019. The company focuses on the travel and leisure markets, developing AI agents that learn users' travel preferences by analyzing their calendars, emails, photos, social media activity, and in-app interactions. XOKind's platform aims to simplify the travel planning and booking process, enhancing user experience by distilling vast amounts of information to support informed decision-making. Through this innovative approach, XOKind seeks to transform how individuals plan their travels.

Aspen Neuroscience, Inc. is a biotechnology company focused on developing induced pluripotent stem cells (iPSCs) to create patient-specific therapies for neurological conditions, particularly Parkinson's disease. Founded in 2018 and based in San Diego, California, the company is advancing its pipeline of products, which includes ANPD001, an autologous neuron replacement therapy for sporadic Parkinson's disease, and ANPD002, a gene-edited autologous neuron replacement therapy targeting familial forms of the disease. Aspen Neuroscience employs innovative genomic approaches in conjunction with stem cell biology to address diseases with significant unmet medical needs, aiming to provide restorative cell therapies that can modify the progression of Parkinson's disease and potentially extend to other affected organs.

GeneDx is a company dedicated to providing personalized and actionable health insights that enhance diagnosis and treatment, ultimately improving health outcomes. Positioned at the intersection of diagnostics and data science, GeneDx combines decades of genomic expertise with the capability to interpret clinical data at scale. The company focuses on accelerating the application of genomic information and large-scale clinical data to establish precision medicine as a standard practice in healthcare. GeneDx leads the transformation of healthcare through its comprehensive exome and genome testing services, leveraging one of the largest rare disease data sets in the world. The business operates through two segments: GeneDx, which generates the majority of its revenue, and Legacy Sema4 diagnostics.

Freenome, Inc. is an artificial intelligence genomics biotech company based in South San Francisco, California, founded in 2014. The company focuses on developing accurate, accessible, and non-invasive blood tests for the early detection of cancer and treatment selection. Utilizing a proprietary multi-omics platform, Freenome employs advanced algorithms to analyze cell-free genomic data, which aids in identifying early-stage cancers and other diseases. This innovative approach aims to transform disease management by enabling timely interventions and proactive treatment strategies. In addition to its diagnostic solutions, Freenome also offers clinical research services to further advance cancer detection and management.

Cradle Genomics, Inc. specializes in fetal genetic analysis and pregnancy health screening solutions, focusing on non-invasive prenatal testing (NIPT) to provide comprehensive insights at the earliest stages of pregnancy. Founded in 2018 and headquartered in San Diego, California, with research and development operations in Detroit, Michigan, the company has developed a platform that analyzes genetic material from fetal cells collected during a first trimester visit. This approach allows pregnant women to receive critical information about their health and the health of their developing fetus without any risk. Cradle Genomics aims to empower expectant parents with knowledge that can guide their decisions throughout the pregnancy journey.